The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
- Author:
Lei LIU
1
;
Zhongzheng XIANG
1
;
Yi LI
2
;
Wei GUO
3
;
Kai YANG
4
;
Jun WANG
1
;
Zhijun SUN
5
;
Guoxin REN
3
;
Jianguo ZHANG
6
;
Moyi SUN
7
;
Wei RAN
8
;
Guilin HUANG
9
;
Zhangui TANG
10
;
Longjiang LI
2
Author Information
- Publication Type:Journal Article
- Keywords: expert consensus; head and neck squamous cell carcinoma; immune checkpoint inhibitors; immunotherapy
- MeSH: Humans; Squamous Cell Carcinoma of Head and Neck/drug therapy*; Immune Checkpoint Inhibitors; Consensus; Neoplasm Recurrence, Local/pathology*; Head and Neck Neoplasms/drug therapy*
- From: West China Journal of Stomatology 2022;40(6):619-628
- CountryChina
- Language:English
- Abstract: Immune checkpoint inhibitors (ICIs) present significant efficacy in the treatment of malignant tumors, and they have been approved as the first-line of treatment for various cancers. Pembrolizumab monotherapy or combined with chemotherapy has been recommended by domestic and foreign guidelines for the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma. Although ICIs represent a milestone in the treatment of head and neck squamous cell carcinoma, potential problems still need to be addressed, such as the selection of the efficacy predictors for ICIs, the evaluation of the tumor response to ICIs, and the treatment of immune hyperprogression and immune-related adverse events. Therefore, to form a relatively unified understanding of ICIs treatment for head and neck squamous cell carcinoma, we integrated the clinical experience of multi-disciplinary experts of head and neck cancers on the basis of current clinical hot issues and finally developed this consensus.